Promising Esketamine Remains On Track As Potential Depression Blockbuster
Published safety and efficacy Phase II data on J&J's esketamine highlights the antidepressant's potential, fanning interest in 2018 pivotal read-outs.
You may also be interested in...
The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.